---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-009864"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T01:23:41.715328+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Aprea Therapeutics Q1 net loss $4.4M; cash runway into Q3 2024; ATRN-119 Phase 1 data expected Q1 2024

## Summary
- Net loss of $4.4M ($1.34 per share) on $31.0M cash; operating loss $4.6M vs $8.1M YoY.
- R&D expenses $1.3M (down from $4.1M YoY) due to legacy trial closeout; G&A $3.4M.
- ATRN-119 Phase 1/2a enrollment continues; initial safety, tolerability, PK data expected Q1 2024.
- ATRN-1051 IND-enabling studies ongoing; IND filing anticipated by end of 2023.
- Closed $4.9M net proceeds from February public offering; appointed Dr. Gabriela Gruia to board.

## SEC filing metadata
- accession: 0001558370-23-009864
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000155837023009864/0001558370-23-009864-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000155837023009864/apre-20230515x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-009864
- JSON: https://secwatch.observer/filing/0001558370-23-009864.json
- Plain text: https://secwatch.observer/filing/0001558370-23-009864.txt

## Key facts
- Earnings Releases
  Aprea Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income net loss of $4.4 million, EPS $1.34 per basic share.
  - Period: the quarter ended March 31, 2023
  - Net income: net loss of $4.4 million
  - EPS: $1.34 per basic share
  - Result: reported results
  source text: The Company reported a net loss of $4.4 million ($1.34 per basic share) on approximately 3.3 million weighted-average common shares outstanding for the quarter ended March 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781983/000155837023009864/0001558370-23-009864-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.